26 studies found for:    newlink
Show Display Options
Rank Status Study
1 Not yet recruiting Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor;   Ependymoma;   Medulloblastoma
Interventions: Drug: Indoximod;   Drug: Temozolomide;   Radiation: Conformal Radiation
2 Not yet recruiting Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: Tergenpumatucel-L;   Drug: Indoximod
3 Recruiting Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable
Interventions: Drug: mFOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: SBRT;   Drug: Gemcitabine
4 Active, not recruiting Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults
Condition: Ebola Viruses
Interventions: Other: Placebo;   Biological: BPSC1001
5 Recruiting Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Metastatic Pancreatic Cancer
Interventions: Drug: Nab-Paclitaxel;   Drug: Gemcitabine;   Drug: Indoximod
6 Recruiting Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab
7 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab
8 Recruiting Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor
Interventions: Drug: Indoximod;   Drug: Temozolomide
9 Recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
10 Recruiting Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Docetaxel;   Other: Placebo;   Drug: Indoximod;   Drug: Paclitaxel
11 Recruiting Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: HyperAcute®-Lung Immunotherapy;   Drug: Gemcitabine;   Drug: Pemetrexed
12 Active, not recruiting Immunotherapy Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy;   Drug: Gemcitabine;   Radiation: 5FU Chemoradiation
13 Terminated IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer;   Lung Cancer;   Melanoma;   Pancreatic Cancer;   Solid Tumors
Intervention: Drug: 1-methyl-D-tryptophan
14 Terminated Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
15 Completed Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
16 Terminated Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Biological: HyperAcute-Lung Cancer Vaccine
17 Completed Vaccine Treatment for Advanced Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Biological: HyperAcute-Melanoma Vaccine
18 Completed Vaccine Treatment for Hormone Refractory Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: HyperAcute-Prostate Cancer Vaccine
19 Terminated Vaccine Treatment for Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Biological: HyperAcute - Breast cancer vaccine
20 Recruiting Immunotherapy Study for Metastatic Renal Cell Cancer
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Clear-cell Renal Cancer;   Recurrent Renal Cell Carcinoma;   Refractory Renal Cell Carcinoma;   Metastatic Kidney Cancer
Intervention: Biological: HyperAcute®-Renal (HAR) Immunotherapy

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Indicates status has not been verified in more than two years